SCHEMBL23958746

SCHEMBL23958746

C=C(c1cc(C(C)(C)O)c(Cl)c(-c2ccc(F)cc2)n1)C1CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.34
CYP11B2 P19099 4/20 0.34
ADRB1 P08588 1/20 0.34
ADRA2A P08913 1/20 0.34
CYP19A1 P11511 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
CFTR P13569 1/20 0.34
ABL1 P00519 1/20 0.33
P2RX7 Q99572 3/20 0.33
CNR1 P21554 3/20 0.32
CNR2 P34972 3/20 0.32
TNIK Q9UKE5 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
ADORA1 P30542 1/20 0.32
SLC34A1 Q06495 2/20 0.32
MAPK14 Q16539 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30006751 1.00 CYP11B1 (0.34) CYP11B1CYP11B2ADRB1ADRA2ACYP19A1
SCHEMBL26727261 0.89 CFTR (0.34) CYP11B1CYP11B2ADRB1ADRA2ACYP19A1
SCHEMBL30007930 0.86 CFTR (0.35) CYP11B1CYP11B2HTR2CHTR2BCFTR
SCHEMBL23958680 0.86 CFTR (0.35) CYP11B1CYP11B2HTR2CHTR2BCFTR
SCHEMBL23958839 0.84 CFTR (0.39) CYP11B1CYP11B2CFTRCNR1CNR2
SCHEMBL23930153 0.79 ADORA2A (0.40) CYP11B1CYP11B2CFTRCNR1CNR2
SCHEMBL30007319 0.79 ADORA2A (0.40) CYP11B1CYP11B2CFTRCNR1CNR2
SCHEMBL26762285 0.78 ADORA2A (0.32) CYP11B1CYP11B2CYP19A1CFTRADORA2A
SCHEMBL28909120 0.78 CYP11B1 (0.33) CYP11B1CYP11B2ADRB1ADRA2ACYP19A1
SCHEMBL26762279 0.78 SCN9A (0.36) CFTRADORA2AADORA2BADORA1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
CN-115461336-A RSV inhibiting 3-substituted quinoline and cinnoline derivatives 爱尔兰詹森科学公司 2022-12-09 CN disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE CYP11B1 857/4885CYP11B2 1181/4885ADRB1 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.